Does BPC-157 actually work?

Nobody knows — because it has never been properly tested in humans.

That is not a figure of speech. A 2025 systematic review searched the literature from 1993 to 2024 and found 36 studies: 35 of them preclinical, and one uncontrolled human survey. There is not a single completed randomized controlled trial of BPC-157, for tendon healing or for anything else. The entire evidence base was graded Level IV-V — the bottom of the pile.

What the evidence actually is

Rats. Genuinely promising rats, to be fair: injected BPC-157 speeds up Achilles tendon and muscle healing in rodent models, and at least one of those results comes from a research group independent of the Zagreb lab that produced most of this literature. But rodent healing results have a long history of not surviving contact with human trials, and that translation step has simply never been attempted here.

The one human musculoskeletal study is a retrospective phone survey of paying clinic patients reporting on their own knee pain. It cannot separate the drug from placebo or from the injury just getting better on its own.

What you should know before buying it

• It is banned in sport. WADA added BPC-157 to the Prohibited List in 2022 under S0 (non-approved substances). No therapeutic use exemption is possible.
• It is not an approved drug anywhere. The only indication the FDA has formally evaluated is ulcerative colitis — not tendons, not muscle.
• There is essentially no human safety data. The regulators say so themselves: WADA's advisory states BPC-157 lacks established safety data, and the systematic review warns that unregulated manufacturing and contamination make adverse effects possible.

The honest bottom line

A real Phase 2 trial finally started recruiting in early 2026 for hamstring strains. It has no results yet. Until it does, anyone telling you BPC-157 heals human injuries is extrapolating from rats and selling you something. It might work. That is a very different statement from "it works."